Literature DB >> 22350025

A Dermatitis Control Program (DeCoP) for head and neck cancer patients receiving radiotherapy: a prospective phase II study.

Sadamoto Zenda1, Shinobu Ishi, Mitsuhiko Kawashima, Satoko Arahira, Makoto Tahara, Ryuichi Hayashi, Seiji Kishimoto, Tomiko Ichihashi.   

Abstract

PURPOSE: We speculated that a systematic program to manage radiation dermatitis might decrease the incidence of severe or fatal cases in head and neck cancer patients receiving radiotherapy. Here, we conducted a prospective phase II study to clarify the clinical benefit of a Dermatitis Control Program (DeCoP) that did not use corticosteroids. PATIENTS AND METHODS: Head and neck cancer patients scheduled to receive definitive or postoperative radiotherapy were enrolled. Radiation dermatitis was managed with a DeCoP consisting of a three-step ladder: Step 1, gentle washing; Step 2, gentle washing and moistening of the wound-healing environment; Step 3, prevention against infection, gentle washing and moistening of the wound-healing environment. The primary endpoint was the incidence of grade 4 dermatitis.
RESULTS: A total of 113 patients were registered between January 2009 and February 2010. Eighty patients received radiotherapy as an initial approach, while the remaining 33 received radiotherapy postoperatively. Grade 3 and 4 dermatitis events occurred in 11 (9.7%) and 0 (0%, 95% confidence interval 0-3.2%) patients, respectively. Median radiation dose at the onset of grade 2 dermatitis was 61.5 Gy (range 36-70 Gy) and median period between onset and recovery was 14 days (range 1-46 days).
CONCLUSION: The Dermatitis Control Program has promising clinical potential. Radiation dermatitis might be manageable if gentle washing and moistening of the wound-healing environment is done.

Entities:  

Mesh:

Year:  2012        PMID: 22350025     DOI: 10.1007/s10147-012-0385-9

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  16 in total

1.  Potent corticosteroid cream (mometasone furoate) significantly reduces acute radiation dermatitis: results from a double-blind, randomized study.

Authors:  A Boström; H Lindman; C Swartling; B Berne; J Bergh
Journal:  Radiother Oncol       Date:  2001-06       Impact factor: 6.280

2.  Can patients wash during radiotherapy to the breast or chest wall? A randomized controlled trial.

Authors:  I R Campbell; M H Illingworth
Journal:  Clin Oncol (R Coll Radiol)       Date:  1992-03       Impact factor: 4.126

Review 3.  The prevention and management of acute skin reactions related to radiation therapy: a systematic review and practice guideline.

Authors:  Amanda Bolderston; Nancy S Lloyd; Rebecca K S Wong; Lori Holden; Linda Robb-Blenderman
Journal:  Support Care Cancer       Date:  2006-06-07       Impact factor: 3.603

Review 4.  Evidence-based skin care management in radiation therapy.

Authors:  Maurene McQuestion
Journal:  Semin Oncol Nurs       Date:  2006-08       Impact factor: 2.315

5.  Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501).

Authors:  Jacques Bernier; Jay S Cooper; T F Pajak; M van Glabbeke; J Bourhis; Arlene Forastiere; Esat Mahmut Ozsahin; John R Jacobs; J Jassem; Kie-Kian Ang; J L Lefèbvre
Journal:  Head Neck       Date:  2005-10       Impact factor: 3.147

6.  Skin treatment with bepanthen cream versus no cream during radiotherapy--a randomized controlled trial.

Authors:  E Løkkevik; E Skovlund; J B Reitan; E Hannisdal; G Tanum
Journal:  Acta Oncol       Date:  1996       Impact factor: 4.089

7.  Effects of Na-sucrose octasulfate on skin and mucosa reactions during radiotherapy of head and neck cancers--a randomized prospective study.

Authors:  J F Evensen; K Bjordal; A B Jacobsen; E Løkkevik; J E Tausjø
Journal:  Acta Oncol       Date:  2001       Impact factor: 4.089

8.  Topical corticosteroid therapy for acute radiation dermatitis: a prospective, randomized, double-blind study.

Authors:  M Schmuth; M A Wimmer; S Hofer; A Sztankay; G Weinlich; D M Linder; P M Elias; P O Fritsch; E Fritsch
Journal:  Br J Dermatol       Date:  2002-06       Impact factor: 9.302

9.  Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.

Authors:  Jan B Vermorken; Eva Remenar; Carla van Herpen; Thierry Gorlia; Ricard Mesia; Marian Degardin; John S Stewart; Svetislav Jelic; Jan Betka; Joachim H Preiss; Danielle van den Weyngaert; Ahmad Awada; Didier Cupissol; Heinz R Kienzer; Augustin Rey; Isabelle Desaunois; Jacques Bernier; Jean-Louis Lefebvre
Journal:  N Engl J Med       Date:  2007-10-25       Impact factor: 91.245

10.  Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.

Authors:  Marshall R Posner; Diane M Hershock; Cesar R Blajman; Elizabeth Mickiewicz; Eric Winquist; Vera Gorbounova; Sergei Tjulandin; Dong M Shin; Kevin Cullen; Thomas J Ervin; Barbara A Murphy; Luis E Raez; Roger B Cohen; Monica Spaulding; Roy B Tishler; Berta Roth; Rosana del Carmen Viroglio; Varagur Venkatesan; Ilya Romanov; Sanjiv Agarwala; K William Harter; Matthew Dugan; Anthony Cmelak; Arnold M Markoe; Paul W Read; Lynn Steinbrenner; A Dimitrios Colevas; Charles M Norris; Robert I Haddad
Journal:  N Engl J Med       Date:  2007-10-25       Impact factor: 91.245

View more
  6 in total

1.  The incidence of radioepidermitis and the dose-response relationship in parotid gland cancer patients treated with 125I seed brachytherapy: incidence of radioepidermitis and the dose-response relationship.

Authors:  Ming-Hui Mao; Jian-Guo Zhang; Lei Zheng; Hong Gao; Jie Zhang; Shu-ming Liu; Ming-wei Huang; Yan Shi
Journal:  Strahlenther Onkol       Date:  2014-09-09       Impact factor: 3.621

2.  A prospective picture collection study for a grading atlas of radiation dermatitis for clinical trials in head-and-neck cancer patients.

Authors:  Sadamoto Zenda; Yosuke Ota; Hiroyuki Tachibana; Hirofumi Ogawa; Shinobu Ishii; Chikako Hashiguchi; Tetsuo Akimoto; Yuichiro Ohe; Yosuke Uchitomi
Journal:  J Radiat Res       Date:  2016-02-04       Impact factor: 2.724

3.  A Multicenter Phase II Trial of Docetaxel, Cisplatin, and Cetuximab (TPEx) Followed by Cetuximab and Concurrent Radiotherapy for Patients With Local Advanced Squamous Cell Carcinoma of the Head and Neck (CSPOR HN01: ECRIPS Study).

Authors:  Sadamoto Zenda; Yosuke Ota; Naomi Kiyota; Susumu Okano; Masato Fujii; Morimasa Kitamura; Shunji Takahashi; Tsutomu Ueda; Nobuya Monden; Takeharu Yamanaka; Makoto Tahara
Journal:  Front Oncol       Date:  2019-01-22       Impact factor: 6.244

4.  Asian expert recommendation on management of skin and mucosal effects of radiation, with or without the addition of cetuximab or chemotherapy, in treatment of head and neck squamous cell carcinoma.

Authors:  Guopei Zhu; Jin-Ching Lin; Sung-Bae Kim; Jacques Bernier; Jai Prakash Agarwal; Jan B Vermorken; Dang Huy Quoc Thinh; Hoi-Ching Cheng; Hwan Jung Yun; Imjai Chitapanarux; Prasert Lertsanguansinchai; Vijay Anand Reddy; Xia He
Journal:  BMC Cancer       Date:  2016-01-27       Impact factor: 4.430

5.  Topical steroid versus placebo for the prevention of radiation dermatitis in head and neck cancer patients receiving chemoradiotherapy: the study protocol of J-SUPPORT 1602 (TOPICS study), a randomized double-blinded phase 3 trial.

Authors:  Sadamoto Zenda; Takuhiro Yamaguchi; Tomoya Yokota; Tempei Miyaji; Tomoe Mashiko; Mari Tanaka; Masahito Yonemura; Misaki Takeno; Tomoka Okano; Toshikatsu Kawasaki; Yuko Nakamori; Shinobu Ishii; Sanae Shimada; Miyuki Kanamaru; Yosuke Uchitomi
Journal:  BMC Cancer       Date:  2018-09-06       Impact factor: 4.430

Review 6.  Quality Assessment in Supportive Care in Head and Neck Cancer.

Authors:  Pierluigi Bonomo; Alberto Paderno; Davide Mattavelli; Sadamoto Zenda; Stefano Cavalieri; Paolo Bossi
Journal:  Front Oncol       Date:  2019-09-18       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.